Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia. The major component of this formulation is green tea extract with a defined composition of polyphenols. Epidemiological studies suggest that phytochemicals in green tea possess beneficial effects on autoimmune and inflammatory diseases. Thus far, there is little evidence to indicate any marked and direct immunomodulatory effect of green tea on T or B lymphocytes. However, there is considerable evidence for green tea polyphenols (GTPs), major phytochemicals found in green tea extract, having properties consistent with effects on cells of tissues that would be protective towards local inflammation.
Patients with subjective complaints of xerostomia will be given a screening questionnaire to complete. If they meet the criteria on this screening form, the research coordinator will be notified and will meet with the patient either immediately or at a scheduled follow-up appointment. The research coordinator will review the information and then explain the details of the study to the patient and obtain informed consent. Once the patient has signed the informed consent, the research coordinator will collect the demographic, medical history, and contact information from the patient. Any information missing will be noted for follow-up investigation by the research coordinator. If a subject is of child bearing age, they will be asked to complete a urine pregnancy test prior to enrollment.[a] First appointment -Screening, consent. [b]Follow appointments- review, then Patients will do VAS questionnaire, QOL questionnaire, Sialometry will be done measuring unstimulated whole saliva and Stimulated whole saliva for 5 min each.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MighTeaFlow | Active Comparator | 4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks |
|
| Xylitol | Active Comparator | 4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MighTeaFlow | Dietary Supplement | 4-6 times daily |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Salivary Flow From Baseline | Change in salivary flow in Xerostomic patients using Green tea lozenges | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Scott S De Rossi, DMD | GHSU | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GHSU Center for Oral Medicine | Augusta | Georgia | 30912 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25240992 | Derived | De Rossi SS, Thoppay J, Dickinson DP, Looney S, Stuart M, Ogbureke KU, Hsu S. A phase II clinical trial of a natural formulation containing tea catechins for xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Oct;118(4):447-454.e3. doi: 10.1016/j.oooo.2014.06.015. Epub 2014 Jul 5. |
Not provided
Not provided
Subjects had a diagnosis of Xerostomia
Potential candidates were identified from a pool of previously diagnosed subjects and new subjects referred to the Clinical Center for Oral Medicine, School of Dentistry, Georgia Regents University
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Green Tea Lozenge | GTP Green tea lozenge: 4-6 times daily |
| FG001 | Placebo | Xylitol lozenge 4 - 6 times daily |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Consented subjects diagnosed with Xerostomia and meeting all inclusion exclusion criteria
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Green Tea Lozenge | GTP Green tea lozenge: 4-6 times daily |
| BG001 | Placebo | Xylitol Green tea lozenge: 4-6 times daily |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Salivary Flow From Baseline | Change in salivary flow in Xerostomic patients using Green tea lozenges | Enrolled subjects completing 8 weeks of treatment | Posted | Mean | Standard Deviation | ml/min | 8 weeks |
|
|
Adverse event data was collected over a period of 27 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | MighTeaFlow | 4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks MighTeaFlow: 4-6 times daily |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Allergic Rhinitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment | itching and scratchiness in the throat |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Scot DeRossi, Chairman of the ORal Medicine & Diagnostic Sciences Department | Georgia Regents University | 706-721-2607 | Sderossi@gru.edu |
Not provided
| ID | Term |
|---|---|
| D014987 | Xerostomia |
| D012859 | Sjogren's Syndrome |
| ID | Term |
|---|---|
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D001172 | Arthritis, Rheumatoid |
Not provided
Not provided
| ID | Term |
|---|---|
| D014993 | Xylitol |
| D001218 | Aspartame |
| ID | Term |
|---|---|
| D013402 | Sugar Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Xylitol | Dietary Supplement | 4-6 times daily |
|
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Participants |
|
|
| 0 |
| 30 |
| 1 |
| 30 |
| EG001 | Xylitol | 4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks Xylitol: 4-6 times daily | 0 | 30 | 2 | 30 |
|
Not provided
Not provided
| D001168 |
| Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D015352 | Dry Eye Syndromes |
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D004151 |
| Dipeptides |
| D009842 | Oligopeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |